Shanghai Biopharmaleader co.,ltd

Date: 18th July 2016
Oritavancin CAS:171099-57-3
If you are going to consult the information about 171099-57-3 from one of the leading 171099-57-3 manufacturers and suppliers in China, Biopharmaleader Co.,Ltd is always at your service.Product InformationCAS NO.171099-57-3?Product NameOritavancinSynonymsLY 333328FormulaC86H97Cl3N10O26Molecular Weight1793.12Spec / Purity98%minSupply CapacityDetailsOritavancin (LY333328/Orbactiv) is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. In December 2008, the US FDA declined to approve it without additional studies, and an EU application was withdrawn. In 2009, the development rights were acquired by The Medicines Company, which has completed clinical trials and submitted a new drug application to the FDA in February 2014. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections in the United States. Its chemical structure is similar to vancomycin. It is a lipoglycopeptide.
Latest News
Contact Information



Building 11, NO. 3802 ShenGang Rd, Xinfei Corporation Home, SongJiang District, Shanghai,201611, China.
Shanghai, 201611


Contact Form